Does anyone have a positive/negative opinion on LeMaitre Vascular (LMAT)?
I am taking a look at now and initial glance seems very interesting
Pros:
\- Niche Monopoly (#1 or #2 market share in the vascular verticals it operates)
\- 70% gross margins
\- Pricing Power (able to follow Transdigm's model of value based pricing)
\- 14 straight years of increasing the dividend
\- positivr track record of M&A
Cons:
\- PE of 37 for a 15%, growth seems a bit pricey
\- narrative wise could be impacted if NVO does well, as less obesity due to GLPs could mean less surgical procedures
What does everyone think? Any other niche monopoly stocks preferred at this time?